Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Stock Short Interest Falls 64.6%

Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) saw a significant decrease in short interest in the month of October. As of October 30th, there was short interest totaling 34 shares, a decrease of 64.6% from the October 15th total of 96 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

Basilea Pharmaceutica Price Performance

Shares of OTCMKTS BPMUF remained flat at $84.00 during trading hours on Friday. Basilea Pharmaceutica has a 1 year low of $59.29 and a 1 year high of $84.00. The company has a quick ratio of 5.97, a current ratio of 6.60 and a debt-to-equity ratio of 0.44. The stock has a 50 day moving average of $77.15 and a two-hundred day moving average of $70.00.

About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.

See Also

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.